Karyopharm Stock Analysis

KPTI
 Stock
  

USD 5.41  0.45  9.07%   

The modest gains experienced by current holders of Karyopharm Therapeut may raise some interest from stockholders. The stock closed today at a share price of 5.41 on 1,724,900 in trading volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.37. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Karyopharm Therapeut partners.
Please see Stocks Correlation.
  
The Karyopharm Therapeut stock analysis report makes it easy to digest most publicly released information about Karyopharm Therapeut and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Karyopharm Stock analysis module also helps to analyze the Karyopharm Therapeut price relationship with some important fundamental indicators such as market cap and management efficiency.

Karyopharm Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Karyopharm Therapeut recorded a loss per share of 2.76. The entity had not issued any dividends in recent years. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people. To find out more about Karyopharm Therapeut contact Michael Kauffman at 617 658-0600 or learn more at www.karyopharm.com.

Karyopharm Therapeut Quarterly Cost of Revenue

939,000

Karyopharm Therapeut Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Karyopharm Therapeut's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Karyopharm Therapeut or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Karyopharm Therapeut has very high historical volatility over the last 90 days
Karyopharm Therapeut has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 234.23 M. Net Loss for the year was (108.07 M) with profit before overhead, payroll, taxes, and interest of 57.42 M.
Karyopharm Therapeut currently holds about 205.31 M in cash with (113.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.59.
Over 90.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Sale by Paulson Richard A of 2314 shares of Karyopharm Therapeut

Karyopharm Therapeut Upcoming and Recent Events

Earnings reports are used by Karyopharm Therapeut to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Karyopharm Therapeut previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of February 2022
Next Financial Report2nd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Karyopharm Largest EPS Surprises

Earnings surprises can significantly impact Karyopharm Therapeut's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-08-07
2014-06-30-0.49-0.55-0.0612 
2016-08-04
2016-06-30-0.76-0.84-0.0810 
2020-05-05
2020-03-31-0.69-0.78-0.0913 
View All Earnings Estimates

Karyopharm Therapeut SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Karyopharm Therapeut prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Karyopharm Therapeut investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Karyopharm Therapeut specific information freely available to individual and institutional investors to make a timely investment decision.
28th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
15th of June 2022
Termination of a Material Definitive Agreement
View
23rd of May 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
9th of May 2022
Unclassified Corporate Event
View
5th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of March 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
28th of March 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
14th of February 2022
Unclassified Corporate Event
View

Karyopharm Therapeut Thematic Classifications

In addition to having Karyopharm Therapeut stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Karyopharm Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Karyopharm Therapeut is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeut backward and forwards among themselves. Karyopharm Therapeut's institutional investor refers to the entity that pools money to purchase Karyopharm Therapeut's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares8.1 M36.6 M
Rubric Capital Management LpCommon Shares3.6 M26.6 M
Highbridge Capital Management LlcDebt31.1 M22.6 M
Vanguard Group IncCommon Shares4.2 M19 M
Walleye Capital LlcCommon Shares1.7 M7.9 M
C Worldwide Group Holding ACommon Shares1.5 M6.8 M
Geode Capital Management LlcCommon Shares1.3 MM
Rice Hall James Associates LlcCommon Shares1.3 M5.9 M
Note, although Karyopharm Therapeut's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Karyopharm Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 370.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Karyopharm Therapeut's market, we take the total number of its shares issued and multiply it by Karyopharm Therapeut's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Karyopharm Profitablity

Karyopharm Therapeut's profitability indicators refer to fundamental financial ratios that showcase Karyopharm Therapeut's ability to generate income relative to its revenue or operating costs. If, let's say, Karyopharm Therapeut is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Karyopharm Therapeut's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Karyopharm Therapeut's profitability requires more research than a typical breakdown of Karyopharm Therapeut's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (46.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (33.68) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.34.
Last ReportedProjected for 2022
Return on Investment(76.15) (82.16) 
Return on Average Assets(0.44) (0.48) 
Return on Average Equity 1.51  1.63 
Return on Invested Capital(0.39) (0.40) 
Return on Sales(0.47) (0.50) 

Management Efficiency

The entity has return on total asset (ROA) of (17.33) % which means that it has lost $17.33 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (891.04) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeut management efficiency ratios could be used to measure how well karyopharm therapeut manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 1.63, while Return on Investment is projected to decrease to (82.16) . Karyopharm Therapeut Asset Turnover is most likely to increase slightly in the upcoming years. The last year's value of Asset Turnover was reported at 0.75. The current Tangible Assets Book Value per Share is estimated to increase to 5.01, while Total Assets are projected to decrease to roughly 277.4 M.
Last ReportedProjected for 2022
Book Value per Share(1.06) (1.09) 
Enterprise Value over EBIT(5.00) (5.39) 
Enterprise Value over EBITDA(5.43) (5.86) 
Price to Book Value(6.10) (6.26) 
Tangible Assets Book Value per Share 4.06  5.01 
Enterprise Value526.2 M671.4 M
Tangible Asset Value305.3 M277.4 M

Technical Drivers

As of the 14th of August 2022, Karyopharm Therapeut secures the Downside Deviation of 5.68, mean deviation of 4.37, and Risk Adjusted Performance of 0.0173. Karyopharm Therapeut technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Karyopharm Therapeut, which can be compared to its peers in the industry. Please verify Karyopharm Therapeut variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Karyopharm Therapeut is priced some-what accurately, providing market reflects its recent price of 5.41 per share. Given that Karyopharm Therapeut has jensen alpha of (0.13), we recommend you to check Karyopharm Therapeut's last-minute market performance to make sure the company can sustain itself at a future point.

Karyopharm Therapeut Price Movement Analysis

The output start index for this execution was thirty with a total number of output elements of thirty-one. The Weighted Moving Average calculates a weight for each value in Karyopharm Therapeut price series with the more recent values given greater weights.
.

Karyopharm Therapeut Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Karyopharm Therapeut insiders, such as employees or executives, is commonly permitted as long as it does not rely on Karyopharm Therapeut's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Karyopharm Therapeut insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Karyopharm Therapeut Predictive Daily Indicators

Karyopharm Therapeut intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Karyopharm Therapeut stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Karyopharm Therapeut Forecast Models

Karyopharm Therapeut time-series forecasting models is one of many Karyopharm Therapeut's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Karyopharm Therapeut's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Karyopharm Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Karyopharm Therapeut stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Karyopharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Karyopharm Therapeut. By using and applying Karyopharm Stock analysis, traders can create a robust methodology for identifying Karyopharm entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(42.15) (45.48) 
EBITDA Margin(0.46) (0.50) 
Gross Margin 0.98  0.93 
Profit Margin(0.59) (0.64) 
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people.

Current Karyopharm Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Karyopharm analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Karyopharm analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
16.0Hold7Odds
Karyopharm Therapeut current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Karyopharm Therapeut, talking to its executives and customers, or listening to Karyopharm conference calls.
Karyopharm Analyst Advice Details

Karyopharm Stock Analysis Indicators

Karyopharm Therapeut stock analysis indicators help investors evaluate how Karyopharm Therapeut stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Karyopharm Therapeut shares will generate the highest return on investment. By understating and applying Karyopharm Therapeut stock analysis, traders can identify Karyopharm Therapeut position entry and exit signals to maximize returns.
Quick Ratio3.47
Fifty Two Week Low4.0000
Revenue Growth104.90%
Shares Short Prior Month15.35M
Average Daily Volume Last 10 Day2.29M
Average Daily Volume In Three Month2.38M
Shares Percent Shares Out22.77%
Gross Margins33.27%
Short Percent Of Float27.13%
Forward Price Earnings-3.25
Float Shares63.09M
Fifty Two Week High14.7300
Enterprise Value To Ebitda-5.70
Fifty Day Average5.0134
Two Hundred Day Average6.8119
Enterprise Value To Revenue1.90
Please see Stocks Correlation. Note that the Karyopharm Therapeut information on this page should be used as a complementary analysis to other Karyopharm Therapeut's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeut price analysis, check to measure Karyopharm Therapeut's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeut is operating at the current time. Most of Karyopharm Therapeut's value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeut's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Karyopharm Therapeut's price. Additionally, you may evaluate how the addition of Karyopharm Therapeut to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Karyopharm Therapeut's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeut. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeut listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
431.8 M
Quarterly Revenue Growth YOY
0.76
Return On Assets
-0.15
Return On Equity
-8.91
The market value of Karyopharm Therapeut is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeut's value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeut's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeut's market value can be influenced by many factors that don't directly affect Karyopharm Therapeut's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeut's value and its price as these two are different measures arrived at by different means. Investors typically determine Karyopharm Therapeut value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeut's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.